S-303 Treated Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Thalassemia Major
Conditions
Thalassemia Major
Trial Timeline
Dec 1, 2012 → Dec 31, 2017
NCT ID
NCT01740531About S-303 Treated Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells
S-303 Treated Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells is a phase 3 stage product being developed by Cerus for Thalassemia Major. The current trial status is completed. This product is registered under clinical trial identifier NCT01740531. Target conditions include Thalassemia Major.
What happened to similar drugs?
7 of 16 similar drugs in Thalassemia Major were approved
Approved (7) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01740531 | Phase 3 | Completed |
Competing Products
20 competing products in Thalassemia Major
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Luspatercept | Merck | Phase 2 | 35 |
| luspatercept | Merck | Phase 2 | 35 |
| ACE-536 | Merck | Phase 2 | 42 |
| luspatercept | Merck | Phase 2 | 35 |
| Deferasirox | Novartis | Approved | 43 |
| Blood sample | Novartis | Pre-clinical | 26 |
| deferasirox + placebo | Novartis | Phase 2 | 35 |
| Zoledronic acid + Placebo | Novartis | Phase 2/3 | 34 |
| deferasirox | Novartis | Approved | 35 |
| deferasirox | Novartis | Phase 3 | 40 |
| ICL670 + deferoxamine | Novartis | Phase 3 | 40 |
| ruxolitinib | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Phase 2 | 35 |
| Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT) | Novartis | Phase 2 | 35 |
| Zoledronic Acid | Novartis | Approved | 43 |
| Deferasirox | Novartis | Phase 2 | 27 |
| Deferasirox | Novartis | Approved | 35 |
| Deferasirox + Deferoxamine (DFO) | Novartis | Phase 2 | 27 |
| Deferasirox | Novartis | Phase 1 | 29 |
| Deferasirox | Novartis | Phase 3 | 40 |